Technical Analysis for EQ - Equillium, Inc.

Grade Last Price % Change Price Change
B 6.5548 -3.04% -0.21
EQ closed down 2.17 percent on Monday, September 27, 2021, on 54 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical EQ trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish -3.04%
Narrow Range Bar Range Contraction -3.04%
NR7 Range Contraction -3.04%
NR7-2 Range Contraction -3.04%
Upper Bollinger Band Walk Strength -3.04%
Inside Day Range Contraction -3.04%
Overbought Stochastic Strength -3.04%
NR7 Range Contraction -5.14%
Upper Bollinger Band Walk Strength -5.14%
Above Upper BB Strength -5.14%
Older End-of-Day Signals for EQ ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 4 hours ago
Down 3% about 4 hours ago
Fell Below Previous Day's Low about 5 hours ago
Down 2 % about 5 hours ago
Down 1% about 5 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Equillium is a biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium’s initial product candidate, EQ001 (itolizumab), is a clinical-stage, first-in-class monocolonal antibody that selectively targets the novel immune checkpoint receptor CD6 and is designed to modulate T cells that drive immuno-inflammation. Itolizumab is a clinically-validated therapeutic with a favorable safety and tolerability profile. Equillium plans to advance EQ001 into clinical development in multiple indications of high unmet medical need and believes EQ001 has the potential to be a best-in-class disease modifying therapeutic.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Immunology Clinical Development Immune System Monoclonal Antibody Inflammation Antibody Autoimmunity Sutro Biopharma Glycoproteins Immune Checkpoint Inflammatory Disorders

Is EQ a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 11.33
52 Week Low 3.47
Average Volume 115,541
200-Day Moving Average 6.33
50-Day Moving Average 5.91
20-Day Moving Average 6.13
10-Day Moving Average 6.34
Average True Range 0.42
ADX 24.29
+DI 26.95
-DI 10.92
Chandelier Exit (Long, 3 ATRs) 5.69
Chandelier Exit (Short, 3 ATRs) 6.58
Upper Bollinger Bands 6.97
Lower Bollinger Band 5.28
Percent B (%b) 0.87
BandWidth 27.71
MACD Line 0.24
MACD Signal Line 0.13
MACD Histogram 0.1075
Fundamentals Value
Market Cap 167.16 Million
Num Shares 24.7 Million
EPS -1.41
Price-to-Earnings (P/E) Ratio -4.78
Price-to-Sales 0.00
Price-to-Book 1.56
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.07
Resistance 3 (R3) 7.08 6.97 7.02
Resistance 2 (R2) 6.97 6.89 6.97 7.00
Resistance 1 (R1) 6.87 6.84 6.82 6.86 6.99
Pivot Point 6.76 6.76 6.74 6.76 6.76
Support 1 (S1) 6.66 6.68 6.61 6.66 6.53
Support 2 (S2) 6.55 6.63 6.55 6.52
Support 3 (S3) 6.45 6.55 6.50
Support 4 (S4) 6.45